Palonosetron: all 74 studies that test it

Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.

• Fosrolapitant Combined With Palonosetron to Prevent Trastuzumab Rezetecan Related CINVRecruitingNCT07726433Phase 2
• Fosrolapitant and Palonosetron for the Prevention of Antibody-drug Conjugate-induced Nausea and VomitingNot yet recruitingNCT07692451Phase 2
• The Safety and Effectiveness of Palonosetron Hydrochloride Capsule Was Used to CINVRecruitingNCT05690802Not applicable
• A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast CancerCompletedNCT03403712Phase 3Results posted
• PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and VomitingCompletedNCT03204279Phase 2Results posted
• Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell TransplantCompletedNCT03097588Phase 2Results posted
• Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With CancerCompletedNCT03040726Phase 2/3Results posted
• Effectiveness of Triple Therapy With Palonosetron for PON ProphylaxisCompletedNCT02635828Phase 4Results posted
• Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) ProphylaxisCompletedNCT02625181Not applicableResults posted
• Postoperative Nausea and Vomiting: Ramosetron Plus Aprepitant vs Palonosetron Plus AprepitantCompletedNCT02597907Not applicableResults posted
• An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and VomitingCompletedNCT02557035Phase 3Results posted
• Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)CompletedNCT01640340Not applicableResults posted
• Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric PatientsCompletedNCT01442376Phase 3Results posted
• Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric PatientsCompletedNCT01395901Phase 3Results posted
• Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant PatientsCompletedNCT01370408Phase 2Results posted
• An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and VomitingCompletedNCT01363479Phase 3Results posted
• A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)CompletedNCT01054456Phase 2Results posted
• Palonosetron Versus Ondansetron for the Prevention of Nausea and VomitingCompletedNCT01031498Phase 2Results posted
• Palonosetron for the Treatment of Nausea and Vomiting in Terminally Ill PatientsTerminatedNCT00982995Phase 2Results posted
• Pilot Study to Assess Palonosetron Versus Ondansetron as Rescue Medication in Subjects That Develop Postoperative Nausea and Vomiting (PONV) in the Postanesthesia Care Unit (PACU)CompletedNCT00967499Phase 2Results posted
• Efficacy of IV Palo With IV Dexamethasone vs IV Palo for Prevention of Immediate & Delayed PONVCompletedNCT00952133Phase 4Results posted
• Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal CancerTerminatedNCT00903396Phase 2Results posted
• Intravenous Palonosetron With Radiotherapy and Concomitant TemozolomideCompletedNCT00900757Phase 2Results posted
• Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation TherapyTerminatedNCT00895245Phase 2Results posted
• Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric PatientsCompletedNCT00828295Phase 3Results posted
• Palonosetron and Hydroxyzine to Reduce Opioid WithdrawalCompletedNCT00661674Not applicableResults posted
• Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With BevacizumabTerminatedNCT00636805Phase 2Results posted
• Multi-day Doses in Prevention of Nausea and EmesisCompletedNCT00600353Phase 2Results posted
• Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical TrialCompletedNCT00475085Phase 3Results posted
• Palonosetron for Prevention of Biochemotherapy Induced Nausea and VomitingCompletedNCT00412425Phase 1/2Results posted
• Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)CompletedNCT00410488Not applicableResults posted
• Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOXCompletedNCT00381862Phase 2Results posted
• Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast CancerCompletedNCT00343863Not applicableResults posted
• Fosrolapitant and Palonosetron for Highly Emetogenic ADC-Induced Nausea and Vomiting in Solid TumorsActive, not recruitingNCT07841210Phase 2
• A Comparison Between Palonosetron Versus Granisetron as PONV Prophylaxis in Scoliotic Patients Undergoing Spine SurgeryCompletedNCT06540885Phase 4
• Palonosetron vs Combination of Granisetron and Dexamethasone in Preventing PONV in Laparoscopic Cholecystectomy.CompletedNCT06043336Phase 4
• Palonosetron vs Ondansetron In PONV Prophylaxis Among Idiopathic Scoliosis PatientsCompletedNCT05956899Phase 4
• Effect of Palonosetron, Ondansetron and Dexamethasone in the Prevention of Postoperative Nausea and VomitingStatus unknownNCT05439798Phase 3
• Protreat-Trial: Prophylactic Antiemetic Treatment of Opioid-induced Nausea and Vomiting (OINV) in Palliative CareCompletedNCT05315999Phase 2
• Evaluate Bioequivalence of Palonosetron (0.25mg/5mL)CompletedNCT04585412Phase 4
• Palonosetron Versus Ondansetron for PONV Prevention in Patients Undergoing ERCPStatus unknownNCT04576390Phase 4
• Effect of Palonosetron on Remifentanil for Preventing Emergence Cough in FemaleCompletedNCT04563260Not applicable
• Post-Operative Nausea and Vomiting in Children Submitted to Strabismus SurgeryStatus unknownNCT04060771Phase 3
• Rolapitant Plus Olanzapine in Multiday Cisplatin ChemotherapyWithdrawnNCT03960151Phase 2
• Postoperative Nausea and Vomiting After Laparoscopic CholecystectomyCompletedNCT03933605Not applicable
• Cisplatin Disposition and Kidney InjuryActive, not recruitingNCT03817970Phase 3
• Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.Status unknownNCT03606369Phase 2/3
• PALONOSETRON X FOSAPREPITANT IN PONVStatus unknownNCT03586817Phase 4
• Proof-of-Concept Trial of Palonosetron and Olanzapine Without Dexamethasone for the Prevention of CINStatus unknownNCT02970643Not applicable
• Compare Between Two Doses of Palonosetron on the Prevention of Postoperative Nausea and Vomiting in Obese PatientsCompletedNCT02941913Phase 4
• Aprepitant for the Prevention of Chemotherapy-induced Nausea and VomitingStatus unknownNCT02933099Phase 3
• The Effects of Anesthetic Techniques and Palonosetron Administration on the Incidence of PONVCompletedNCT02809378Phase 4
• Comparison of Palonosetron Versus Combination of Palonosetron and Dexamethasone for Preventing Postoperative Vomiting in Patients Receiving Fentanyl by Patient-controlled Analgesia After Minor Orthopedic SurgeryCompletedNCT02744508Not applicable
• Prophylactic Antiemetic Efficacy of Palonosetron Versus Ondansetron for the Prophylaxis of Postoperative Nausea and Vomiting (PONV) in Women Over 60 Years Undergoing Laparoscopic CholecystectomyCompletedNCT02541019Phase 4
• Prophylactic Antiemetic Efficacy of Palonosetron Versus Ondansetron for Cesarean Sections Under Regional AnesthesiaCompletedNCT02468323Phase 4
• Prospective Study of Palonosetron in Radiation Induced Nausea and Vomiting (RINV)CompletedNCT02388750Phase 2
• Palonosetron Plus Aprepitant Versus Palonosetron in Preventing Nausea and Vomiting in Leukemic PatientsStatus unknownNCT02205164Phase 2
• MEtoclopramide, DExamethasone or Axoli to Prevent or Delay Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based ChemotherapyCompletedNCT02135510Phase 3
• Prevention of Intrathecal Morphine Induced Pruritus: Comparison of Ondansetron and PalonosetronCompletedNCT01952626Not applicable
• The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic ChemotherapyCompletedNCT01909856Phase 2
• The Effect of Palonosetron on the QTc Interval During Perioperative PeriodCompletedNCT01650961Not applicable
• Therapeutic Efficacy and Safety of Palonosetron in Treatment of Postoperative Nausea and VomitingCompletedNCT01568268Phase 3
• Efficacy and Safety of Palonosetron Hydrochloride in the Prevention of Nausea and VomitingCompletedNCT01481831Phase 4
• Prophylactic Effects of Ondansetron, Ramosetron, and Palonosetron on Patient-Controlled Analgesia Related Nausea and Vomiting After Urologic Laparoscopic SurgeryCompletedNCT01169805Not applicable
• Aprepitant for Prevention of Acute and Delayed Nausea and Vomiting in Patients Receiving a High-emetogenic Dose of Cyclophosphamide for Peripheral Blood Stem Cells HarvestingStatus unknownNCT01088022Phase 3
• Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Palonosetron in Cancer Treated With ChemotherapyCompletedNCT01046240Phase 1/2
• Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic ChemotherapyCompletedNCT01018758Phase 2
• Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594)CompletedNCT00687011Phase 4
• Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED)CompletedNCT00684463Phase 4
• An Efficacy and Safety Study of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in the Chinese Cancer PatientsCompletedNCT00666783Phase 2
• Safety and Efficacy of Palonosetron in Preventing Chemotherapy-induced Nausea and VomitingCompletedNCT00503386Phase 2
• AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic ProgenitorsCompletedNCT00415103Phase 4
• Comparative Study of Palonosetron With Granisetron as a Control in Patients Receiving Highly Emetogenic ChemotherapyCompletedNCT00359567Phase 3
• Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.CompletedNCT00306735Phase 2

← Palonosetron overview